Adjuvant Chemotherapy for Node-Negative Breast Cancer

References

• National Cancer Institute. Clinical alert from the National Cancer Institute 1988
   Google Scholar
• Treatment of early-stage breast cancer. NIH Consens Dev Conf Consens Statement 1990; 8(6)
   Google Scholar
• Nissen-Meyer R, Host H, Kjellgren K. Treatment of node negative breast cancer patients with short course of chemotherapy after surgery. NCI Monogr 1986; 1: 125–128
   PubMedGoogle Scholar
• Nissen-Meyer R, Host H, Kjellgren K, Mansson B, Norin T. Neoadjuvant chemotherapy in breast cancer: as single perioperative treatment and with supplementary long-term chemotherapy. Adjuvant Therapy of Cancer V, SE Salmon. Grune & Stratton, Orlando, FL 1987; 253–261
   Google Scholar
• Mansour E G, Gray R, Shatila A H, Osborne C K, Tormey D C, Gilchrist K W, Cooper M R, Falkson G. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An in-tergroup study. N Engl J Med 1989; 320: 485–490
   PubMed Web of Science ®Google Scholar
• Mansour E G, Eudey L, Shatila A H, Tormey D C, Osborne C K, Gilchrist K W, Cooper M R, Gray R, Falkson G. Adjuvant therapy in node-negative breast cancer. Is it necessary for all patients? An intergroup study. Adjuvant Therapy of Breast Cancer, SE Salmon. WB Saunders, Philadelphia 1990; 174–189
   Google Scholar
• Senn H J, Barrett-Mahler A-R, Jungi W F, OSAKO. Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer patients: 10 year results. Eur J Cancer Clin Oncol 1989; 25: 513–525
   PubMedGoogle Scholar
• Jakesz R, Reiner G, Schemper M, Reiner A, Blijham G, Rainer H, Dittrich D, Spona J, Schutte B, Reynders M, Van Assche C, Waldhor T. Significant survival benefit of node-negative breast cancer patients treated with adjuvant chemotherapy: seven-year results. Recent Results Cancer Res 1989; 115: 180–185
   PubMedGoogle Scholar
• Bonadonna G, Valagussa P. The contribution of medicine to the primary treatment of breast cancer. Cancer Res 1988; 48: 2314–2324
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P, Militerni A, Buzzoni R, Zambetti M, Ferrari L, Brambilla C, Silvestrini R, Veronesi U. Milan adjuvant and neoadjuvant studies in stage I and II resectable breast cancer. Adjuvant Therapy of Cancer VI, SE Salmon. WB Saunders, Philadelphia 1990; 169–173
   Google Scholar
• Fisher B, Redmond C, Dmitrov NV, Bowman D, Legault-Poisson S, Wickerham DL, Wolmark N, Fisher ER, Margolese R, Sutherland C, Glass A, Foster R, Caplan R. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989; 320: 473–478
   PubMed Web of Science ®Google Scholar
• Fisher B, Redmond C, Wickerham L, Wolmark N, Bowman D, Couture J, Dimitrov N V, Margolese R, Legault-Poisson S, Rob-idoux A. Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials. Ann Intern Med 1989; 111: 703–712
   PubMed Web of Science ®Google Scholar
• Fisher B, Wolmark N, Wickerham D L, Redmond C K. Current NSABP trials of adjuvant therapy for breast cancer. Adjuvant Therapy of Cancer VI, SE Salmon. WB Saunders, Philadelphia 1990; 276–285
   Google Scholar
• Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989; 320: 491–496
   PubMed Web of Science ®Google Scholar
• Morrison J M, Howell A, Kelly K A, Grieve R J, Monypenny I J, Walker R A, Waterhouse J AH. West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. II. Patients without involved axillary lymph nodes. Br J Cancer 1989; 60: 919–924
   PubMed Web of Science ®Google Scholar
• Morrison J M, Kelly K A, Howell A, Grieve R J, Monypenny I J, Walker R, Waterhouse J A. West Midlands Oncology Association trials of adjuvant chemotherapy for operable breast cancer. Adjuvant Therapy of Cancer VI, SE Salmon. WB Saunders, Philadelphia 1990; 204–209
   Google Scholar
• Caffier H, Rotte K, Haeggqwist O. Adjuvant chemotherapy versus postoperative irradiation in node negative breast cancer. Adjuvant Therapy of Cancer IV, SE Jones, SE Salmon. Grune & Stratton, Orlando, FL 1984; 417–424
   Google Scholar
• Semiglazov V, Bavli J L, Moiseyenko V M, Rzhankov S V, Mig-manova N S, Popova R T, Seleznyov I K, Kremen B V, Kostetskaya T V, Barash N J, Ivanova O A, Kuchieru A G. Clinical trials on Sledge and McCaskill-Stevens adjuvant chemotherapy for breast cancer. Cancer 1985; 57: 1957–1960
   Web of Science ®Google Scholar
• CRC Adjuvant Breast Trial Working Party. Cyclohosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 1988; 57: 604–607
   PubMed Web of Science ®Google Scholar
• Williams C J, Buchanan R B, Taylorl Hall V, Cooke T, Nicholson R, Griffiths K. Adjuvant chemotherapy for Tl-2, NO, Mo estrogen receptor negative breast cancer: preliminary results of a randomised trial. Adjuvant Therapy of Cancer V, SE Salmon. Grune & Stratton, Orlando, FL 1987; 233–241
   Google Scholar
• Roe D J, Dalton W S, Mosley K, Salmon S E. Long-term follow-up on adjuvant adriamycin/cyclophosphamide for node negative breast cancer. Adjuvant Therapy of Cancer VI, SE Salmon. WB Saunders, Philadelphia 1990; 190–195
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Treatment of Early Breast Cancer. Oxford University Press, Oxford 1990
   Google Scholar
• Reiner G, Jakesz R, Schemper M, Reiner A, Kolb R, Rainer H, Dittrich C, Spona J, Blijham G, Schutte B, Reynders M, Van Asche C. Prognostic impact of flow cytometry and interaction with adjuvant chemotherapy in patients with inoperable breast cancer. Adjuvant Therapy of Cancer VI, SE Salmon. WB Saunders, Philadelphia 1990; 333–338
   Google Scholar
• Wall J G, Weiss R B. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma. Am J Med 1989; 87: 501–504
   PubMed Web of Science ®Google Scholar
• Arriagada R, Rutqvist L E. Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies. Vol. 1. Lancet 1991; 338: 535–538
   PubMed Web of Science ®Google Scholar
• Siminoff L A, Fetting J H, Abeloff M B. Doctor-patient communication about breast cancer adjuvant therapy. J Clin Oncol 1989; 7: 1192–2000
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P. Systemic therapy in resectable breast cancer. Hematol/Oncol Clin North Am 1989; 3(4)727–742
   PubMed Web of Science ®Google Scholar
• Henderson I C, Hayes D F, Parker L. Adjuvant systemic therapy for patients with node-negative tumors. Cancer 1990; 65: 2132–2147
   PubMed Web of Science ®Google Scholar
• Gelber R D, Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Cin Oncol 1986; 4: 1772–1779
   PubMed Web of Science ®Google Scholar
• Hillner B E. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node negative breast cancer: a decision analysis model. N Engl J Med 1991; 324: 160–168
   PubMed Web of Science ®Google Scholar
• McGuire W L. Adjuvant therapy of node-negative breast cancer. N Engl J Med 1989; 320: 525
   PubMed Web of Science ®Google Scholar
• Jakesz R, Kolb R, Schemper M, Rainer H, Dittrich C, Reiner A. Adjuvant chemotherapy in node-negative breast cancer patients. Adjuvant Therapy of Cancer V, SE Salmon. Grune & Stratton, Orlando, FL 1987; 223–231
   Google Scholar